Enhancement of Proliferation and Invasion of Gastric Cancer Cell by KDM5C Via Decrease in p53 Expression

Gastric cancer is a malignancy with high incidence and the second leading cause of cancer death worldwide. Development of efficient therapies against gastric cancer is urgent. Until now, the mechanisms of gastric cancer genesis remain elusive. The KDM5C is a histone demethylase that promotes cancer cell growth and is enriched in drug-resistant cancer cells. But the pathogenic breadth and mechanistic aspects of this effect relative to gastric cancer have not been defined. In present study, we found that KDM5C was overexpressed in gastric cancer cell lines and gastric cancer tissues but not in normal gastric tissues. The proliferation and invasive potential of gastric cancer cells was significantly increased by ectopic expression of KDM5C. Contrarily, RNA interference targeting KDM5C in gastric cancer cells significantly decreased the proliferation and invasive potential of cells. Moreover, we also found that the expression of p53 was modulated by KDM5C. Cells with overexpression of KDM5C exhibited greatly decreased p53 expression, whereas silencing of KDM5C expression dramatically increased p53 expression at both the messenger RNA and protein levels. Inhibition of p53 by small-interfering RNA reversed the shKDM5C-induced proliferation and invasion. Our results collectively suggested that KDM5C played a role in gastric cancer cells proliferation and invasion, which may be partly associated with the p53 expression.

[1]  Karl Mechtler,et al.  Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells. , 2006, Genes & development.

[2]  Yang Shi,et al.  Reversal of Histone Lysine Trimethylation by the JMJD2 Family of Histone Demethylases , 2006, Cell.

[3]  Yang Shi,et al.  Dynamic regulation of histone lysine methylation by demethylases. , 2007, Molecular cell.

[4]  J. Ragoussis,et al.  The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth. , 2010, Cancer research.

[5]  B. Ponder,et al.  The Histone Demethylase JMJD2B Plays an Essential Role in Human Carcinogenesis through Positive Regulation of Cyclin-Dependent Kinase 6 , 2011, Cancer Prevention Research.

[6]  T. Mak,et al.  Histone Demethylase JMJD2B Functions as a Co-Factor of Estrogen Receptor in Breast Cancer Proliferation and Mammary Gland Development , 2011, PloS one.

[7]  Jie Yang,et al.  HIF-1α-induced histone demethylase JMJD2B contributes to the malignant phenotype of colorectal cancer cells via an epigenetic mechanism. , 2012, Carcinogenesis.

[8]  L. Chamley,et al.  Transient JMJD2B-Mediated Reduction of H3K9me3 Levels Improves Reprogramming of Embryonic Stem Cells into Cloned Embryos , 2012, Molecular and Cellular Biology.

[9]  Pierre Saintigny,et al.  Recent advances in non-small cell lung cancer biology and clinical management. , 2012, Discovery medicine.

[10]  Guo‐Jun Zhang,et al.  The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis , 2013, Scientific Reports.

[11]  C. Robson,et al.  The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover , 2013, Nucleic acids research.

[12]  Yunshan Wang,et al.  CUL4A is overexpressed in human pituitary adenomas and regulates pituitary tumor cell proliferation , 2014, Journal of Neuro-Oncology.

[13]  Weiguo Hu,et al.  The Association Between TP53 Arg72Pro Polymorphism and Lung Cancer Susceptibility: Evidence from 30,038 Subjects , 2013, Lung.

[14]  Yunshan Wang,et al.  The role of uPAR in epithelial-mesenchymal transition in small airway epithelium of patients with chronic obstructive pulmonary disease , 2013, Respiratory Research.

[15]  M. Hendzel,et al.  The oncogenic potential of Jumonji D2 (JMJD2/KDM4) histone demethylase overexpression. , 2013, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[16]  Z. Liao,et al.  Associations between Single-Nucleotide Polymorphisms in the PI3K–PTEN–AKT–mTOR Pathway and Increased Risk of Brain Metastasis in Patients with Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[17]  E. Wang,et al.  BRIT1 regulates p53 stability and functions as a tumor suppressor in breast cancer. , 2013, Carcinogenesis.

[18]  Lung cancer patients with an abnormal gene benefit from targeted therapy , 2013, Cancer.

[19]  Ying Sun,et al.  Estrogen promotes stemness and invasiveness of ER-positive breast cancer cells through Gli1 activation , 2014, Molecular Cancer.

[20]  Annette Lee,et al.  P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency. , 2013, Critical reviews in oncology/hematology.

[21]  R. Janknecht,et al.  KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. , 2013, Cancer research.

[22]  Yunshan Wang,et al.  Involvement of CUL4A in Regulation of Multidrug Resistance to P-gp Substrate Drugs in Breast Cancer Cells , 2013, Molecules.

[23]  M. Strasberg-Rieber,et al.  p53 inactivation decreases dependence on estrogen/ERK signalling for proliferation but promotes EMT and susceptility to 3-bromopyruvate in ERα+ breast cancer MCF-7 cells. , 2014, Biochemical pharmacology.

[24]  Y. Akiyama,et al.  Jumonji domain-containing protein 2B silencing induces DNA damage response via STAT3 pathway in colorectal cancer , 2014, British Journal of Cancer.

[25]  J. Gray,et al.  CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. , 2014, Cancer research.

[26]  R. Janknecht,et al.  Stimulation of β-catenin and colon cancer cell growth by the KDM4B histone demethylase. , 2014, International journal of oncology.